Metaplastic breast cancer

Greenberg, Darrilyn; McIntyre, Heather; Bierre, Tony

doi:10.1111/j.1440-1673.2004.01305.x

Cited by 13 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13,18 Radiologic findings can change according to the component the tumor contains. 19 Metoplastic carcinoma of the breast is seen as a spiculated mass with irregular margins that often has intermediate to high signal intensity in T2W images and is low or isointense in T1W images in MRI. 13 Metaplastic carcinoma of the breast may be treated with breast-conserving surgery in suitable cases.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological features of metaplastic breast carcinoma

Hasdemir¹,

Tokgöz²,

Köybaşıoğlu³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

Metaplastic carcinoma of the breast is relatively rare and, in our series, its incidence was 0.6%. According to its immunohistochemical characteristics, MpBC can be interpreted as a subgroup of triplenegative breast cancers (TNBC). Five of the presented patients resembled the subgroup of TNBC with a basaloid phenotype. The chemotherapy regimens suggested in the treatment of MpBC are platin in the epithelial subgroup and high-dose anthracycline in the mesenchymal subgroup. There is a need of new studies that evaluate different choices of treatment as MpBC has a bad prognosis and an aggressive nature.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological features of metaplastic breast carcinoma

Hasdemir¹,

Tokgöz²,

Köybaşıoğlu³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Table 1 shows the data reported in the 19 papers. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] Epidemiology MBC is very rare and constitutes only 0.08-0.2% of all breast malignancies. 20 Invasive ductal carcinomas (IDC) constitute 70-80% of all breast malignancy.…”

Section: Collected Datamentioning

confidence: 99%

Metaplastic breast carcinoma: A case report and systematic review of the literature

Toumi¹,

Bullen²,

Tang

et al. 2011

Pathology International

View full text Add to dashboard Cite

A 78-year-old retired woman was diagnosed with metaplastic breast carcinoma (MBC), a rare tumor, in our hospital. We reviewed 15 articles with a total of 1328 patients to determine the epidemiology, clinical features, biomarkers, histology, management and outcome of patients with this tumor. The mean age at presentation is 58.5 years (range 32-83). Eighty-one percent of patients presented either with a breast mass or abnormal mammographic finding. Twenty-three percent of patients had a family history of breast cancer. Estrogen receptors were only found in 12%, progesterone receptors in 10% and HER2 in 6% of patients. The main method of treatment was mastectomy (66.9%) in combination with chemotherapy (57%) and radiotherapy (47%). Five-year disease-free survival ranged between 40% and 84% and 5-year overall survival ranged between 64 and 83%. We have further reviewed the nature of this disease in the light of advancement in genetics, such as microarray gene expression profiling. The relationship of MBC with triple-negative tumor and basal-like tumor is discussed. It is hoped that advances in genetics and biomarkers will bring forward the era of personalized medicine in the treatment of breast carcinoma.

show abstract

“…Metaplastic breast cancer (MBC) is a very rare type of invasive breast cancer in which the original cell type, usually glandular epithelium, differentiates into either epithelial and/or mesenchymal cell types with glandular and nonglandular components [1,2]. According to the World Health Organization (WHO), MBC includes several subtypes, including low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, squamous cell carcinoma, spindle cell carcinoma, mixed metaplastic carcinoma, myoepithelial carcinoma, and metaplastic carcinoma with mesenchymal differentiation-notably chondroid, osseous, and other types of mesenchymal differentiation [3].…”

Section: Introductionmentioning

confidence: 99%

Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

et al. 2020

View full text Add to dashboard Cite

Background: Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear. Methods: We compared the clinical outcomes between women with metaplastic breast cancer and women with triple-negative breast cancer diagnosed between 1994 and 2014. Metaplastic breast cancer patients were matched 1:3 to triple-negative breast cancer patients by stage and age at diagnosis. Distant disease-free survival (DDFS) and overall survival (OS) were estimated using Kaplan Meier methods and Cox proportional hazard regression models. Immune checkpoint markers were characterized by immunohistochemistry in a subset of samples.Results: Forty-four metaplastic breast cancer patients (stage I 14%; stage II 73%; stage III 11%; stage IV 2%) with an average age of 55.4 (± 13.9) years at diagnosis. Median follow-up for the included metaplastic breast cancer and triple-negative breast cancer patients (n = 174) was 2.8 (0.1-19.0) years. The DDFS and OS between matched metaplastic breast cancer and triple-negative breast cancer patients were similar, even when adjusting for clinical covariates (DDFS: HR = 1.64, p = 0.22; OS: HR = 1.64, p = 0.26). Metaplastic breast cancer samples (n = 27) demonstrated greater amount of CD163 in the stroma (p = 0.05) and PD-L1 in the tumor (p = 0.01) than triplenegative breast cancer samples (n = 119), although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples (p = 0.02). Conclusions:Patients with metaplastic breast cancer had similar outcomes to those with triple-negative breast cancer based on DDFS and OS. The immune checkpoint marker profile of metaplastic breast cancers in this study may prove useful in future studies attempting to demonstrate an association between immune profile and survival.

show abstract

Metaplastic breast cancer

Cited by 13 publications

References 14 publications

Clinicopathological features of metaplastic breast carcinoma

Clinicopathological features of metaplastic breast carcinoma

Metaplastic breast carcinoma: A case report and systematic review of the literature

Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

Contact Info

Product

Resources

About